COMPOSITION FOR PREVENTION, ALLEVIATION, OR TREATMENT OF ATOPIC DERMATITIS DISEASE

Abstract

There is provided a composition for prevention, alleviation, or treatment of atopic dermatitis diseases, a functional food and a pharmaceutical composition, each including same, and a composition for alleviation of atopic dermatitis diseases, including an Impatiens arguta extract as an active ingredient.

Claims

1. A composition for alleviation of atopic dermatitis diseases, comprising an Impatiens arguta extract as an active ingredient.

2. The composition of claim 1, wherein the extract is an extract by water, ethanol, or a mixed solvent thereof.

3. The composition of claim 1, further comprising an Artemisia annua extract.

4. The composition of claim 3, wherein the Impatiens arguta extract is used as a first raw material, and the composition further comprises at least one of selected from the group consisting of Raphanus sativus extract, Pyrus pyrifolia extract and Artemisia annua extract as a second raw material.

5. The composition of claim 4, wherein the extracts of the first raw material and the second raw material are mixed in a weight ratio of 1:0.2 to 1.5.

6. The composition of claim 1, further comprising an extract of at least one of Ziziphus jujuba, Schisandrae chinensis, Lycium chinense, Alnus japonica, Cuscuta semen, and Rhodiola rosea. The composition of claim 1, further comprising honey.

8. A health functional food for prevention or alleviation of atopic dermatitis diseases, comprising the composition according to claim 1.

9. The health functional food of claim 8, wherein the health functional food is a natural tea composition.

10. A pharmaceutical composition for prevention, alleviation, or treatment of atopic dermatitis diseases, comprising the composition according to claim 1.

11. A cosmetic composition for prevention or alleviation of atopic dermatitis diseases, comprising the composition according to claim 1.

Description

MODE OF DISCLOSURE

[0073] Hereinafter, the present invention will be described with reference to Examples and Experimental Examples. However, the scope of the present invention is not limited to these Examples and Experimental Examples.

Preparation Example 1: Sample Preparation

[0074] An Impatiens arguta extract (extraction part: leaves) was prepared, and the atopic dermatitis disease amelioration activity was confirmed. The extract was obtained in a powder form by adding 10 times the weight of 70% ethanol to dry powder of Impatiens arguta leaves, extracting twice at 50° C. for 6 hours, filtering, concentrating under reduced pressure and freeze-drying.

[0075] Artemisia annua was prepared in the same way as the Impatiens arguta extract and obtained in powder form.

[0076] Raphanus sativus and Pyrus pyrifolia extracts were filtered through a 3M filter pulverized with a blender, and liquid extracts and solid components were separated. The liquid component was autoclaved at 120° C. at 1.5 atm for 15 minutes, cooled at room temperature, titrated to pH 6.2-6.6, and stored at 4° C.

[0077] Extracts of Ziziphus jujuba, Schisandrae chinensis, Lycium chinense, Alnus japonica, Cuscuta semen, and Rhodiola rosea were obtained in the same manner as the Impatiens arguta leaves to obtain powders, respectively.

[0078] For honey, commercially available natural honey from Mt. Jiri (Mohyanggol Farm in Mt. Jiri) was used.

EXAMPLES

[0079] By using the extracts, compositions were obtained as shown in Table 1 below.

TABLE-US-00001 TABLE 1 (Unit: wt %) Example Example Example Comparative Comparative Ingredient 1 2 3 Example 1 Example 2 Impatiens 90 45 40 arguta Artemisia 45 25 45 90 annua Raphanus 25 45 sativus Ziziphus 5 5 5 5 5 jujuba Schisandrae 3 3 3 3 3 chinensis Honey 2 2 2 2 2 Total 100 100 100 100 100

<Preparation Example>Manufacture of Atopic Dermatitis Animal Model

[0080] In order to confirm in the animal model whether it is effective on atopic dermatitis, an animal model in which atopic dermatitis is induced was manufactured. Specifically, the hair of the back area of each of 5 to 6-week-old Nc/Nga mice (Japanese fancy mice, Nishiki-Nezumi, Japan) was cleanly removed and left for 24 hours to heal the microscopic wounds on the skin after hair removal was completed, followed by applying 200 ul of 1% DNCB solution (acetone: olive oil=3:1) to the back area, thereby causing dermatitis. After 4 days, 150 ul of 0.2% DNCB solution was applied 2˜3 times a week to the back area for a period of 4 to 5 weeks to sufficiently induce dermatitis and to peel off all the crusts on the back area, facilitating the penetration of a therapeutic drug, and, when scratching intensified with the formation of new dermatitis, DNCB treatment was stopped. As such, an atopic dermatitis animal model was manufactured.

<Experimental Example 1>Anti-atopic Effect of Extract in Atopic Animal Model

[0081] <1> Sensory Evaluation

[0082] In order to confirm the anti-atopic effect of the compositions of Examples and Comparative Examples in atopic animal models, the extract was treated in an atopic dermatitis induced animal model, and sensory evaluation was performed by using a clinical visual evaluation method. Specifically, in the animal model of Preparation Example 1 in which atopic dermatitis was induced, 10 days after the treatment with the compositions of Examples and Comparative Examples was completed, 30% 1,3-butylene glycol was applied to a control group, 200 ul of each of the compositions of Examples and Comparative Examples was applied to the experimental group twice a day for a period of 8 weeks, and then sensory evaluation was performed by using a clinical visual evaluation method at intervals of 2 weeks. The visual evaluation result was expressed as the total of the scores respectively evaluated for five evaluation items, which are erythema, pruritus & dry skin, edema & escoriation, erosion, and lichenification. These evaluation items were scored as none (0), mild (1), severe (2), and extreme (3), and the scores ranged from a minimum of 0 to a maximum of 15. In general, when the dermatitis is induced by using DNCB, it can be determined that the dermatitis has reached its peak at about 12 to 13 points.

[0083] As a result, compared to an untreated group and the control group treated only with butylene glycol or the compositions of Comparative Examples, all of the compositions of Examples according to the present invention showed a tendency to improve an atopic condition. Therefore, it was confirmed that the composition according to the present invention exhibited a remarkable effect in alleviating the symptoms in an atopic animal model.

<Preparation Example 1> Preparation of Pharmaceutical Preparations

[0084]

TABLE-US-00002 <1-1> Preparation of Powders Composition of Example 1 20 mg Lactose 20 mg

[0085] After mixing the above ingredients, the powder was prepared by filling the mixture in an airtight cloth.

TABLE-US-00003 <1-2> Preparation of Tablets Composition of Example 1  10 mg Corn starch 100 mg Lactose 100 mg Magnesium stearate  2 mg

[0086] After mixing the above ingredients, tablets were prepared by tableting according to a conventional tablet manufacturing method.

<Preparation Example 2> Preparation of Foods

[0087] Foods containing the composition of Example 1 of the present invention were prepared as follows.

TABLE-US-00004 <Preparation of health drinks> Composition of Example 1 100 mg Citric acid 100 mg Oligosaccharide 100 mg Plum concentrate  2 mg Taurine 100 mg Purified water added Total 500 ml

[0088] After mixing the above ingredients according to a conventional health drink manufacturing method, the mixture was stirred and heated at 85° C. for about 1 hour, and the resulting solution was filtered and obtained in a sterilized 1 L container, followed by sealing and sterilizing, and then storing in a refrigerator, to then be used for manufacturing the health beverage composition of the present invention.

[0089] The composition ratio was prepared by mixing ingredients suitable for relatively favorite beverages in a preferred embodiment, but the mixing ratio may be arbitrarily modified according to regional and national preferences, such as demand class, demand country, and purpose of use.

<Preparation Example 3> Preparation of Cosmetics

[0090] <Softening (Skin) Lotion>

[0091] In order to prepare a softening lotion for atopic skin, containing the composition of Example 1 of the present invention, the softening lotion may be prepared according to the manufacturing method in the conventional cosmetic field by mixing in the following manner.

TABLE-US-00005 Composition of Example 1 20 wt % 1,3-butylene glycol  3.0 wt % Glycerin  5.0 wt % Polyoxyethylene (60) hydrogenated castor oil  0.2 wt % Ethanol  8.0 wt % Citric acid 0.02 wt % Sodium citrate 0.06 wt % Preservative trace amount Perfume trace amount Purified water To 100